NICE approval for denosumab in cancer

The osteoclast-targeting antibody denosumab has been accepted for NHS use in patients with bone metastases.

Denosumab targets the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts
Denosumab targets the RANK ligand, which is essential for the differentiation, function and survival of osteoclasts

Denosumab (Xgeva) is recommended as an option for preventing skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than of the prostate.

It may be used if:

  • bisphosphonates would otherwise be prescribed and
  • the manufacturer provides denosumab with the discount agreed in the patient access scheme.

Denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer. Skeletal events are defined as pathological fracture, radiation to bone, spinal cord compression or surgery to bone.

Denosumab is also licensed as Prolia for the treatment of osteoporosis in postmenopausal women and for the prevention of bone loss associated with hormonal therapy in men with prostate cancer. It is accepted by NICE for restricted use in the postmenopausal setting.

NICE guidance on denosumab in adults with bone metastases

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases